Trial
NCT00602329
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
National Cancer Institute (NCI)
Condition
Colorectal Cancer
Intervention
bevacizumab
Why stopped
Due to Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-28